AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27295865 — intervention group
Group type: COMPARATOR
Intervention: 20% sucrose
Number of subjects: 11
Study 24695064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA)
Number of subjects: 14
Study 24695064 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 14
Study 22710397 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (34 g administered at 8 p.m. the night before the examination)
Number of subjects: 50
Study 22710397 — intervention group
Group type: COMPARATOR
Intervention: No preparation (no laxative administered)
Number of subjects: 50
Study 20670236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine for palatal block
Number of subjects: 45
Study 20670236 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline for palatal block
Number of subjects: 45
Study 20670236 — intervention group
Group type: COMPARATOR
Intervention: No block (control group)
Number of subjects: 45
Study 17204156 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and drug abuse and dependence (AAD/DAD) assessment using standardized procedures and structured interviews.
Number of subjects: 998
Study 17204156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use among prisoners.
Number of subjects: 998
Study 17204156 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse and dependence (AAD) prevalence.
Number of subjects: 998
Study 17204156 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of AAD and DAD profiles.
Number of subjects: 998
Study 17204156 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular screening and treatment programs for AAD/DAD in prison.
Number of subjects: 998
Study 16123473 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 20
Study 16123473 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RHI)
Number of subjects: 20
Study 12215236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg/24 h)
Number of subjects: 16
Study 12215236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12215236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 16
Study 10051966 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan (6 mg)
Number of subjects: 127
Study 10051966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 7981578 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing hormone (GHRH; 100 micrograms)
Number of subjects: 12
Study 7981578 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose tolerance test
Number of subjects: 12
Study 7981578 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 12
Study 2493400 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (0.2 mg SC or 1.2 mg IN per day)
Number of subjects: 26
Study 2493400 — intervention group
Group type: COMPARATOR
Intervention: Danazol (800 mg per day)
Number of subjects: 26
Study 2493400 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 26
Study 2493400 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 26
Study 1105370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol-HCl 300 mg/24 hr
Number of subjects: 67
Study 1105370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 1105370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol-HCl
Number of subjects: 67
Study 31642130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention workbook plus device (WD)
Number of subjects: 72
Study 31642130 — intervention group
Group type: COMPARATOR
Intervention: Intervention workbook only (WO)
Number of subjects: 72
Study 31642130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 30366723 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ropivacaine
Number of subjects: 116
Study 30366723 — intervention group
Group type: COMPARATOR
Intervention: Saline nebulization (placebo)
Number of subjects: 116
Study 27779370 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning strategies (implementation intentions and coping plans)
Number of subjects: 71
Study 27779370 — intervention group
Group type: COMPARATOR
Intervention: No planning (control condition)
Number of subjects: 71
Study 26898264 — intervention group
Group type: EXPERIMENTAL
Intervention: Z applicator
Number of subjects: 30
Study 26898264 — intervention group
Group type: EXPERIMENTAL
Intervention: IR applicator
Number of subjects: 30
Study 26898264 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy (Control)
Number of subjects: 30
Study 24550190 — intervention group
Group type: COMPARATOR
Intervention: AG (1 µg/kg/h)
Number of subjects: 17
Study 24550190 — intervention group
Group type: COMPARATOR
Intervention: AG+UAG
Number of subjects: 17
Study 24550190 — intervention group
Group type: EXPERIMENTAL
Intervention: UAG (4 µg/kg/h)
Number of subjects: 17
Study 24550190 — intervention group
Group type: EXPERIMENTAL
Intervention: AG
Number of subjects: 17
Study 24550190 — intervention group
Group type: EXPERIMENTAL
Intervention: UAG
Number of subjects: 17
Study 23061628 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5mg/kg in a single intravenous infusion)
Number of subjects: 14
Study 19545556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean telomere repeat copy number to single gene copy number (T/S ratio) in cases (VTE)
Number of subjects: 216
Study 19545556 — intervention group
Group type: COMPARATOR
Intervention: Mean telomere repeat copy number to single gene copy number (T/S ratio) in controls
Number of subjects: 216
Study 19545556 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-variable adjusted analysis of T/S ratios
Number of subjects: 216
Study 17314192 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS (120% of motor threshold; 1200 stimuli/day for 5 days)
Number of subjects: 16
Study 17314192 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 16
Study 15064593 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Tai Chi for 1.5 h, 6x wk for 8 wk
Number of subjects: 49
Study 11759263 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group (n = 100)
Number of subjects: 154
Study 11759263 — intervention group
Group type: COMPARATOR
Intervention: Cross-validation group (n = 54)
Number of subjects: 154
Study 9773697 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal sufentanil 2, 5, or 10 microg (2 mL volume) and epidural saline (10 mL)
Number of subjects: 100
Study 9773697 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 5, 12.5, or 25 mg and intrathecal saline (2 mL volume)
Number of subjects: 100
Study 9773697 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intrathecal sufentanil (1, 2.5, and 5 microg) plus epidural bupivacaine (2.5, 6.25, or 12.5 mg)
Number of subjects: 100
Study 7828395 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (15 ml of potassium chloride with 0.9 mmol K per ml, three times a day) in group 2 (72 patients on diuretics)
Number of subjects: 320
Study 7828395 — intervention group
Group type: COMPARATOR
Intervention: 2-day preparation of 15 g magnesium sulphate and 10 mg bisacodyl twice daily in group 1 (55 patients on diuretics without potassium supplements)
Number of subjects: 320
Study 7828395 — intervention group
Group type: COMPARATOR
Intervention: 2-day preparation of 15 g magnesium sulphate and 10 mg bisacodyl twice daily in group 3 (97 patients)
Number of subjects: 320
Study 7828395 — intervention group
Group type: COMPARATOR
Intervention: 1-day preparation of 2.4 mg sennoside per kg in group 4 (96 patients)
Number of subjects: 320
Study 3338014 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with chlorambucil for 2 years
Number of subjects: 162
Study 3338014 — intervention group
Group type: COMPARATOR
Intervention: Follow-up alone
Number of subjects: 162
Study 2149806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene preparation
Number of subjects: 50
Study 2149806 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel preparation
Number of subjects: 50
Study 2149806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 50
Study 2149806 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study 788625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixyrazine
Number of subjects: 197
Study 788625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 31651350 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.25 mg dexamethasone intravenously after 8 hours of hypoxia with an FiO2 of 12%
Number of subjects: 20
Study 31651350 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo intravenously after 8 hours of hypoxia with an FiO2 of 12%
Number of subjects: 20
Study 28735202 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit™ exercise therapy
Number of subjects: 90
Study 28735202 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 90
Study 28735202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise therapy)
Number of subjects: 90
Study 26416936 — intervention group
Group type: EXPERIMENTAL
Intervention: 6400 IU vitamin D3/day
Number of subjects: 334
Study 26416936 — intervention group
Group type: COMPARATOR
Intervention: 400 IU vitamin D3/day
Number of subjects: 334
Study 23666250 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 567
Study 23666250 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers related to inflammation (C-reactive protein, pentraxin 3, GDF-15, interleukin 6)
Number of subjects: 567
Study 23666250 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers related to extracellular matrix remodelling (syndecan-1, periostin)
Number of subjects: 567
Study 23666250 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide, TNF-αR1a, GDF-15
Number of subjects: 567
Study 21158922 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 53
Study 21158922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 53
Study 18762944 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily plus calcium (1,000 mg) and vitamin D (800 IU)
Number of subjects: 316
Study 18762944 — intervention group
Group type: COMPARATOR
Intervention: Control (daily alfacalcidol (1 microg) plus calcium (500 mg) for those with prevalent vertebral fractures; daily vitamin D (800 IU) plus calcium (1,200 mg) for those without previous vertebral fractures)
Number of subjects: 316
Study 18762944 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 316
Study 18762944 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 316
Study 17786099 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg controlled-release doxycycline
Number of subjects: 0
Study 15042289 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-pharyngeal CPAP
Number of subjects: 40
Study 15042289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson prongs
Number of subjects: 40
Study 15042289 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Flow system
Number of subjects: 40
Study 15042289 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-pharyngeal tube
Number of subjects: 40
Study 11247106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 51
Study 11247106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9744511 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin and vinblastine followed by surgery
Number of subjects: 31
Study 9744511 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 31
Study 9744511 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 31
Study 9744511 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 31
Study 9744511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality treatment (chemotherapy and surgery)
Number of subjects: 31
Study 7925789 — intervention group
Group type: EXPERIMENTAL
Intervention: Full vision of the hand and unrestricted movement of the eyes
Number of subjects: 0
Study 7925789 — intervention group
Group type: EXPERIMENTAL
Intervention: No vision of the hand
Number of subjects: 0
Study 7925789 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual fixation on a stationary LED
Number of subjects: 0
Study 7925789 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral visual field target
Number of subjects: 0
Study 7925789 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual pursuit of a second target moving at the same speed and direction
Number of subjects: 0
Study 2839021 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 244
Study 2839021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 31412001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 29419331 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy single fraction EBRT
Number of subjects: 112
Study 29419331 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy in five fractions EBRT
Number of subjects: 112
Study 27250881 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (35 mg/m2, 6 cycles)
Number of subjects: 60
Study 27250881 — intervention group
Group type: COMPARATOR
Intervention: 3 weekly cisplatin (100 mg/m2, 3 cycles)
Number of subjects: 60
Study 25269046 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Drainage (LD)
Number of subjects: 148
Study 25269046 — intervention group
Group type: COMPARATOR
Intervention: External Ventricular Drainage (EVD)
Number of subjects: 148
Study 21344320 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to TV contingent on physical activity
Number of subjects: 30
Study 21344320 — intervention group
Group type: COMPARATOR
Intervention: Free access to TV
Number of subjects: 30
Study 19948879 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose deferoxamine (2.5 mg/kg/week)
Number of subjects: 42
Study 19948879 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose deferoxamine (5 mg/kg/week)
Number of subjects: 42
Study 18608737 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg for 3 consecutive days, administered in three monthly pulses
Number of subjects: 57
Study 15950634 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐alpha plus infliximab (400 microg/mL)
Number of subjects: 31
Study 15950634 — intervention group
Group type: COMPARATOR
Intervention: TNF‐alpha only
Number of subjects: 31
Study 11809166 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related potential N270 in Parkinson's disease patients
Number of subjects: 64
Study 11809166 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related potential P300 in match condition
Number of subjects: 64
Study 11809166 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched normal controls)
Number of subjects: 64
Study 10582984 — intervention group
Group type: EXPERIMENTAL
Intervention: IV/IA r-TPA therapy
Number of subjects: 35
Study 10582984 — intervention group
Group type: COMPARATOR
Intervention: Placebo/IA therapy
Number of subjects: 35
Study 8688271 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped message encouraging to stop smoking
Number of subjects: 363
Study 8688271 — intervention group
Group type: COMPARATOR
Intervention: Blank tape
Number of subjects: 363
Study 2053568 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy
Number of subjects: 0
Study 6140702 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from long-term benzodiazepine treatment
Number of subjects: 22
Study 6140702 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 22
Study 31600795 — intervention group
Group type: EXPERIMENTAL
Intervention: LV tissue Doppler MPI
Number of subjects: 79
Study 31600795 — intervention group
Group type: COMPARATOR
Intervention: LV conventional spectral Doppler MPI
Number of subjects: 79
Study 31600795 — intervention group
Group type: EXPERIMENTAL
Intervention: RV tissue Doppler MPI
Number of subjects: 79
Study 31600795 — intervention group
Group type: COMPARATOR
Intervention: RV conventional spectral Doppler MPI
Number of subjects: 79
Study 31600795 — intervention group
Group type: EXPERIMENTAL
Intervention: LV tissue Doppler MPI in obese subjects
Number of subjects: 79
Study 31600795 — intervention group
Group type: COMPARATOR
Intervention: LV conventional spectral Doppler MPI in obese subjects
Number of subjects: 79
Study 31600795 — intervention group
Group type: EXPERIMENTAL
Intervention: RV tissue Doppler MPI in obese subjects
Number of subjects: 79
Study 31600795 — intervention group
Group type: COMPARATOR
Intervention: RV conventional spectral Doppler MPI in obese subjects
Number of subjects: 79
Study 31600795 — intervention group
Group type: COMPARATOR
Intervention: Intraobserver variability for LV conventional spectral Doppler
Number of subjects: 79
Study 31600795 — intervention group
Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 79
Study 29845639 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine at 60, 85, 110, 135, and 160 mg/L
Number of subjects: 75
Study 29845639 — intervention group
Group type: EXPERIMENTAL
Intervention: Eugenol at 40, 80, 120, 160, and 200 mg/L
Number of subjects: 75
Study 29845639 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol at 50, 75, 150, 200, and 250 mg/L
Number of subjects: 75
Study 26451499 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF combined with autogenous anterior iliac crest bone graft
Number of subjects: 24
Study 26451499 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft alone (control group)
Number of subjects: 24
Study 24639242 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB‐FA
Number of subjects: 40
Study 24639242 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB‐FA-CWI
Number of subjects: 40
Study 24639242 — intervention group
Group type: COMPARATOR
Intervention: PL-CWI
Number of subjects: 40
Study 22971253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health counseling
Number of subjects: 99
Study 22971253 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 99
Study 21395142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone, 6 mg/kg/day
Number of subjects: 100
Study 21395142 — intervention group
Group type: COMPARATOR
Intervention: Oral propafenone, 6.6 mg/kg/day
Number of subjects: 100
Study 17270521 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey and carbohydrate (CH(2)O) supplementation
Number of subjects: 3
Study 17270521 — intervention group
Group type: COMPARATOR
Intervention: Soy drink
Number of subjects: 3
Study 16227697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (CEZ)
Number of subjects: 157
Study 16227697 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/sulbactam (SBT/ABPC)
Number of subjects: 157
Study 12047205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed exercises in addition to standard post-operative mobilization protocol
Number of subjects: 42
Study 12047205 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative mobilization protocol (Control)
Number of subjects: 42
Study 10354124 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin (UH)
Number of subjects: 20
Study 10354124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 20
Study 10354124 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin infusion
Number of subjects: 20
Study 7749942 — intervention group
Group type: EXPERIMENTAL
Intervention: HHT (7.5% NaCl/10% HES 200)
Number of subjects: 23
Study 7749942 — intervention group
Group type: COMPARATOR
Intervention: HES (0.9% NaCl/10% HES 200)
Number of subjects: 23
Study 1702569 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiksin (0.125-0.25 g orally)
Number of subjects: 0
Study 1702569 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiksin (1-2 tablets at least 2 days apart)
Number of subjects: 0
Study 7460760 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone/methadyl acetate treatment
Number of subjects: 50
Study 7460760 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study 31208714 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Vivomixx® 1800 billion units/day) for 60 days
Number of subjects: 40
Study 31208714 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Vivomixx® 1800 billion units/day) for 120 days
Number of subjects: 40
Study 31208714 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 40
Study 31208714 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 120 days
Number of subjects: 40
Study 27810723 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD severity
Number of subjects: 366
Study 27810723 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 366
Study 27810723 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous suicide attempt
Number of subjects: 366
Study 27810723 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative cognitions about the self and interpersonal support
Number of subjects: 366
Study 25891753 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training group
Number of subjects: 31
Study 25891753 — intervention group
Group type: COMPARATOR
Intervention: Isotonic training group
Number of subjects: 31
Study 22720766 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed fluoxetine treatment (once-weekly for 24 weeks, then self-administered for 12 weeks)
Number of subjects: 137
Study 22720766 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 137
Study 21872629 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study 19885996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cort80 (6.3 mg/hr/70 kg)
Number of subjects: 36
Study 19885996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cort160 (12.6 mg/hr/70 kg)
Number of subjects: 36
Study 19885996 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 36